ArticleCritical care (London, England)2014
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
Article in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 8 syntheses or guidelines pooled it, 240 citations in OpenAlex.
- Antimicrobial interventions in multi drug resistance providencia associated infection; a systematic review and meta-analysis of case reports.BMC infectious diseases · 2026Pooled it
- Population Pharmacokinetics of Tigecycline: A Systematic Review.Drug design, development and therapy · 2022Pooled it
- Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.Advances in therapy · 2020Pooled it
- Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis.Medicine · 2019Pooled it
- Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.Critical care (London, England) · 2017Pooled it
- The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2017Pooled it
- Task force on management and prevention of Acinetobacter baumannii infections in the ICU.Intensive care medicine · 2015Guideline
- Risk factors for tigecycline-associated drug-induced liver injury in critically Ill patients: a 2020-2023 retrospective study from a Chinese hospital.BMC infectious diseases · 2026Article
- The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study.BMC infectious diseases · 2026Article
- Eravacycline as Salvage Therapy for Severe Intra-Abdominal Infections Caused by Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Safety and Efficacy of Nebulized Inhalation of Polymyxin B Sulfate for Carbapenem-Resistant Gram-Negative Bacterial Pneumonia: A Multi-Center, Prospective, Observational Study.Infection and drug resistance · 2026Article
- Observational
- Next-generation hybrid bioanalytical platforms and clinical integration of TDM technologies for precision monitoring to optimize last-resort antibiotic therapy.Frontiers in pharmacology · 2026Review
- Tigecycline pharmacodynamics in the hollow fiber system ofbioRxiv : the preprint server for biology · 2025Article
- Management of Carbapenem Resistant Gram-Negative Infections.Indian journal of pediatrics · 2025Review
- Eravacycline as a last resort for difficult-to-treat resistantJAC-antimicrobial resistance · 2025Article
- Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy.Scientific reports · 2025Article
- Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses.
methodsWe conducted a retrospective study of prospectively collected data in the ICU of a teaching hospital in Rome. Data from all patients treated with TGC for a microbiologically confirmed infection were analyzed. The safety profile and efficacy of high dosing regimen use were investigated.
resultsOver the study period, 54 patients (pts) received TGC at a standard dose (SD group: 50 mg every 12 hours) and 46 at a high dose (HD group: 100 mg every 12 hours). Carbapenem-resistant Acinetobacter.baumannii (blaOXA-58 and blaOXA-23 genes) and Klebsiella pneumoniae (blaKPC-3 gene) were the main isolated pathogens (n = 79). There were no patients requiring TGC discontinuation or dose reduction because of adverse events. In the ventilation-associated pneumonia population (VAP) subgroup (63 patients: 30 received SD and 33 HD), the only independent predictor of clinical cure was the use of high tigecycline dose (odds ratio (OR) 6.25; 95% confidence interval (CI) 1.59 to 24.57; P = 0.009) whilst initial inadequate antimicrobial treatment (IIAT) (OR 0.18; 95% CI 0.05 to 0.68; P = 0.01) and higher Sequential Organ Failure Assessment (SOFA) score (OR 0.66; 95% CI 0.51 to 0.87; P = 0.003) were independently associated with clinical failure.
conclusionsTGC was well tolerated at a higher than standard dose in a cohort of critically ill patients with severe infections. In the VAP subgroup the high-dose regimen was associated with better outcomes than conventional administration due to Gram-negative MDR bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.